They would also help to determine the true contribution of CD8+CD103+ TRM cells and the identified costimulatory molecules in the success of immune checkpoint blockade immunotherapies in a minor subpopulation of cancer patients, and to improve current T-cell-based cancer immunotherapeutic approaches such as adoptive T-cell therapies (Figure 2). Here, CD8A is linked to cancer.